Clinuvel Pharmaceuticals (ASX:CUV) broadens DNA repair programme
Clinuvel Pharmaceuticals (CUV) is expanding its clinical programme to test Scensse’s ability…
Clinuvel Pharmaceuticals Limited (ASX:CUV)
$29.04
-0.35 (-1.19%)
MCAP $1.452B
Last trade
16.10pm 29/11/2021
20mins delayed
Latest Announcements
22/11/2021CUVClinuvel Pharmaceuticals Limited
18/11/2021CUVClinuvel Pharmaceuticals Limited
11/11/2021CUVClinuvel Pharmaceuticals Limited
244
MCap
10/11/2021CUVClinuvel Pharmaceuticals Limited
552
MCap
10/11/2021CUVClinuvel Pharmaceuticals Limited
288
MCap
08/11/2021CUVClinuvel Pharmaceuticals Limited
08/11/2021CUVClinuvel Pharmaceuticals Limited
08/11/2021CUVClinuvel Pharmaceuticals Limited
1,287
MCap
Company Overview
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). It is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.
